1. Search Result
Search Result
Results for "

genotype

" in MedChemExpress (MCE) Product Catalog:

60

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

2

Peptides

5

Natural
Products

3

Recombinant Proteins

4

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13998
    Dasabuvir
    10+ Cited Publications

    ABT-333

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir
  • HY-136267

    HCV Infection
    HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .
    HCV-IN-30
  • HY-10465
    Daclatasvir dihydrochloride
    Maximum Cited Publications
    46 Publications Verification

    BMS-790052 dihydrochloride; EBP 883 dihydrochloride

    HCV Infection
    Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir dihydrochloride
  • HY-10466
    Daclatasvir
    Maximum Cited Publications
    46 Publications Verification

    BMS-790052; EBP 883

    HCV Infection
    Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir
  • HY-13997
    Ombitasvir
    5+ Cited Publications

    ABT-267

    HCV Infection
    Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
    Ombitasvir
  • HY-13998A

    ABT-333 sodium

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir sodium
  • HY-13998R

    HCV DNA/RNA Synthesis Infection
    Dasabuvir (Standard) is the analytical standard of Dasabuvir. This product is intended for research and analytical applications. Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
    Dasabuvir (Standard)
  • HY-115982

    HCV Protease Infection
    NS5A-IN-3 (Compound 15) is a potent inhibitor of NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5A-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-3
  • HY-N8188

    HCV HCV Protease Infection
    Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC50=1.35?μM) .
    Dehydrojuncusol
  • HY-10465R

    HCV Infection
    Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .
    Daclatasvir dihydrochloride (Standard)
  • HY-U00213

    R803

    HCV Infection
    Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC50, ~30 nM) than against the genotype 2a replicon (EC50, ~1,000 nM).
    Furaprofen
  • HY-D1350

    Fluorescent Dye
    5-ROX-alkyne is a rhodamine dye that labels DNA fragments. It enables visualization of the results of capillary electrophoresis genotyping experiments and gel shift experiments.
    5-ROX-alkyne
  • HY-115981

    HCV Protease Infection
    NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NS5A-IN-2
  • HY-12731

    HCV Infection
    GSK2236805 is a potent hepatitis C virus inhibitor with pEC50 values of 10.4, 11.1 for HCV genotype 1a (gt1a) and gt1b, respectively .
    GSK2236805
  • HY-D1311

    Fluorescent Dye
    R110 azide, 6-isomer is an isomer of rhodamine dye with an azide group that labels DNA fragments. It enables visualization of the results of capillary electrophoresis genotyping experiments and gel shift experiments.
    R110 azide, 6-isomer
  • HY-15789
    Elbasvir
    5+ Cited Publications

    MK-8742

    HCV Infection
    Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
    Elbasvir
  • HY-125182

    Cyclophilin HCV Infection
    SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .
    SMCypI C31
  • HY-119393

    Others Others
    Olanzapine N-oxide is a compound under investigation for the metabolism of antipsychotic compounds. Olanzapine N-oxidation and N-demethylation are catalyzed by different enzymes, and its plasma concentration and clearance are not affected by a single factor, such as a specific genotype or smoking behavior.
    Olanzapine N-oxide
  • HY-123649

    Others Others
    MK-4882 is an HCV NS5A inhibitor with activity in reducing viral load in a chimpanzee model of HCV infection, but with issues of viral breakthrough, prompting the development of compounds with greater potency against more genotypes and NS5A resistance mutations.
    MK-4882
  • HY-101662

    ABT-530

    HCV Infection
    Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
    Pibrentasvir
  • HY-16784

    IDX719; IDX18719

    HCV HCV Protease Infection
    Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC50s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons .
    Samatasvir
  • HY-12429
    Beclabuvir
    3 Publications Verification

    BMS-791325

    HCV Infection
    Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM .
    Beclabuvir
  • HY-W060316

    3-Hydroxy-5-isopropyltropolone

    HBV DNA/RNA Synthesis Infection
    β-Thujaplicinol (3-Hydroxy-5-isopropyltropolone) is an inhibitor of hepatitis B virus (HBV) ribonuclease H. β-Thujaplicinol inhibits RNAseHs of HBV genotypes D and H with IC50 values of 5.9 and 2.3 μM, respectively .
    β-Thujaplicinol
  • HY-125473

    Endogenous Metabolite Infection
    IDX375 is a novel non-nucleoside inhibitor with selective inhibitory activity against HCV NS5B. IDX375 has good selectivity for genotypes 1a and 1b. The structure and binding site of IDX375 were confirmed by X-ray cocrystal studies .
    IDX375
  • HY-15602
    Ledipasvir
    30+ Cited Publications

    GS-5885

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir
  • HY-15602C

    GS-5885 hydrochloride

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM .
    Ledipasvir hydrochloride
  • HY-15789R

    HCV Infection
    Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
    Elbasvir (Standard)
  • HY-19921

    HCV Infection
    JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.
    JTK-853
  • HY-147885

    HCV Infection
    HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC50 value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication .
    HCV-IN-41
  • HY-150760

    GSK2485852

    HCV Inflammation/Immunology
    GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC50 value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC50s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively .
    GSK5852
  • HY-P10517

    SFT

    HIV Infection
    Sifuvirtide (SFT) is a potent HIV fusion inhibitor. Sifuvirtide inhibits HIV-1 mediated cell fusion in a dose-dependent manner and is highly potent against infection by primary and laboratory-adapted HIV-1 isolates of multiple genotypes. Sifuvirtide can be used in the research of anti-HIV drugs .
    Sifuvirtide
  • HY-12429A

    BMS-791325 hydrochloride

    HCV Infection
    Beclabuvir (BMS-791325) hydrochloride is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM .
    Beclabuvir hydrochloride
  • HY-N7934

    (-)-Trachelogenin

    HCV Infection Neurological Disease Inflammation/Immunology
    Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .
    Trachelogenin
  • HY-12530
    Velpatasvir
    5+ Cited Publications

    GS-5816

    HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir
  • HY-12689
    Mitapivat
    1 Publications Verification

    AG-348

    Pyruvate Kinase Metabolic Disease
    Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .
    Mitapivat
  • HY-12689B

    AG-348 hemisulfate

    Pyruvate Kinase Metabolic Disease
    Mitapivat hemisulfate is an orally active pyruvate kinase allosteric activator. Mitapivat hemisulfate increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat hemisulfate can be used in study of PK deficiency .
    Mitapivat hemisulfate
  • HY-15602S

    GS-5885-d6

    HCV SARS-CoV Infection
    Ledipasvir-d6 is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].
    Ledipasvir-d6
  • HY-12689A

    AG-348 hemisulfate sesquihydrate

    Pyruvate Kinase Metabolic Disease
    Mitapivat hemisulfate sesquihydrate (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .
    Mitapivat hemisulfate sesquihydrate
  • HY-12633

    HCV Inflammation/Immunology
    GS-6620 is potent and selective pangenotype HCV inhibitor against HCV replicons of genotypes 1 to 6 (EC50: 0.048 to 0.68 μM). GS-6620 shows limited activities against other viruses, maintaining only some of its activity against the closely related bovine viral diarrhea virus (EC50, 1.5 μM) .
    GS-6620
  • HY-P4037

    HCV Infection
    HCV Core Protein (107-114) is a least immunogenic residue of the major linear HCV core regions. HCV Core Protein (107-114) is identified as the binding site within the region 101-118, which contains two residues differing between genotypes Ⅰ/Ⅱ and Ⅲ/Ⅵ. HCV Core Protein (107-114) might be a potential site for dissemination of HCV serotypes .
    HCV Core Protein (107-114)
  • HY-12530R

    HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir (Standard)
  • HY-10235
    Telaprevir
    40+ Cited Publications

    VX-950

    HCV Protease HCV SARS-CoV Infection
    Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL pro activity .
    Telaprevir
  • HY-15256A

    BI 201335 sodium

    HCV Protease Infection
    Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .
    Faldaprevir sodium
  • HY-19840

    GS-9857

    HCV Protease Infection Cancer
    Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .
    Voxilaprevir
  • HY-15256

    BI 201335

    HCV Protease Infection
    Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .
    Faldaprevir
  • HY-N6798
    Myriocin
    4 Publications Verification

    Thermozymocidin; ISP-I

    HCV Antibiotic Infection
    Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection .
    Myriocin
  • HY-15298
    Grazoprevir
    25+ Cited Publications

    MK-5172

    HCV Protease HCV SARS-CoV Infection
    Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir inhibits SARS-CoV-2 3CL pro activity .
    Grazoprevir
  • HY-15298A
    Grazoprevir potassium salt
    25+ Cited Publications

    MK-5172 potassium salt

    HCV HCV Protease SARS-CoV Infection
    Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir potassium salt inhibits SARS-CoV-2 3CL pro activity .
    Grazoprevir potassium salt
  • HY-15298C

    MK-5172 sodium salt

    HCV HCV Protease SARS-CoV Infection
    Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively . Grazoprevir sodium salt inhibits SARS-CoV-2 3CL pro activity .
    Grazoprevir sodium salt
  • HY-10118
    Filibuvir
    2 Publications Verification

    HCV DNA/RNA Synthesis Infection
    Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .
    Filibuvir

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: